Dr. David Reardon on Treating Glioblastoma Patients With EGFRvIII-Mutations
David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, on the need to identify glioblastoma (GBM) patients with the EGFRvIII mutation in their tumor.
David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, on the need to identify glioblastoma (GBM) patients with the EGFRvIII mutation in their tumor. Although this mutation is only present in roughly 30% of patients, there is a new treatment, rindopepimut (CDX-110), which has proven to be well tolerated and can improve survival in these patients.
Reardon says it is important for community oncologists to be able to identify GBM patients with this mutation so they can receive the treatment. He says testing to identify that mutation is routinely done at most medical centers.
T-DXd Combinations Effective in HER2+ Gastric and GEJ Cancer
September 14th 2024Findings from the DESTINY-Gastric03 study support the further exploration of the antibody-drug conjugate trastuzumab deruxtecan for the first-line treatment of patients with advanced HER2+ gastric, esophageal, and GEJ cancers.
Read More
LITESPARK-005 Trial of Belzutifan Shows Survival Benefits in Advanced Clear Cell RCC
September 13th 2024A statistically significant improvement in progression-free survival and objective response rate was seen with belzutifan treatment in patients with previously treated patients with advanced clear cell renal cell carcinoma.
Read More
In SCLC, Upfront BMS-986012 Plus Nivolumab/Chemotherapy Has Potential
September 13th 2024The addition of BMS-986012 to nivolumab and chemotherapy showed promising signals of improved overall survival in patients with extensive-stage small cell lung cancer compared to nivolumab and chemotherapy alone.
Read More
